Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone

Flavio Doni, Paolo Della Bella, Antoine Kheir, Margherita Manfredi, Carlo Piemonti, Elio Staffiere, Andrea Rimondini, Cesare Fiorentini

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Transesophageal overdrive atrial pacing is effective and safe for atrial flutter termination. The influence of antiarrhythmic drug therapy on this procedure is controversial. In this study, we investigated whether oral propafenone may facilitate this procedure. Thirty patients with type I atrial flutter were randomized into 2 groups in which transesophageal pacing was attempted: group A, without treatment; and group B, after oral administration of propafenone 600 mg. Transesophageal pacing was effective in interrupting atrial flutter in 53% of patients (8 of 15) in group A and in 87% of patients (13 of 15) in group B. A significant lengthening of the flutter cycle was observed with respect to the baseline in patients given propafenone (261 ± 23 vs 217 ± 25, p <0.01). Sinus rhythm resumed at a shorter paced cycle in group A patients (166 ± 13 vs 187 ± 14 ms, p <0.01). The transesophageal threshold for stable atrial capture was significantly lower in group A (20.5 ± 0.2 vs 23.3 ± 1.2, p <0.01). In no patient was the threshold for atrial capture higher than the pain threshold. We did not observe abrupt enhancement of atrioventricular conduction. We conclude that propafenone is effective and safe when used with transesophageal pacing in the termination of atrial flutter. The slowing effect of the drug on intraatrial conduction and the possible stabilizing effect on the reentry circuit appear to be outweighed by the positive effect of propafenone on the excitable gap of the circuit, facilitating its capture and accounting for the beneficial effect of the drug on arrhythmia termination.

Original languageEnglish
Pages (from-to)1243-1246
Number of pages4
JournalThe American Journal of Cardiology
Volume76
Issue number17
DOIs
Publication statusPublished - Dec 15 1995

Fingerprint

Propafenone
Atrial Flutter
Pain Threshold
Anti-Arrhythmia Agents
Pharmaceutical Preparations
Oral Administration
Cardiac Arrhythmias
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. / Doni, Flavio; Bella, Paolo Della; Kheir, Antoine; Manfredi, Margherita; Piemonti, Carlo; Staffiere, Elio; Rimondini, Andrea; Fiorentini, Cesare.

In: The American Journal of Cardiology, Vol. 76, No. 17, 15.12.1995, p. 1243-1246.

Research output: Contribution to journalArticle

Doni, Flavio ; Bella, Paolo Della ; Kheir, Antoine ; Manfredi, Margherita ; Piemonti, Carlo ; Staffiere, Elio ; Rimondini, Andrea ; Fiorentini, Cesare. / Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. In: The American Journal of Cardiology. 1995 ; Vol. 76, No. 17. pp. 1243-1246.
@article{b56bc1aa8f6844bf899ffaca788b27c1,
title = "Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone",
abstract = "Transesophageal overdrive atrial pacing is effective and safe for atrial flutter termination. The influence of antiarrhythmic drug therapy on this procedure is controversial. In this study, we investigated whether oral propafenone may facilitate this procedure. Thirty patients with type I atrial flutter were randomized into 2 groups in which transesophageal pacing was attempted: group A, without treatment; and group B, after oral administration of propafenone 600 mg. Transesophageal pacing was effective in interrupting atrial flutter in 53{\%} of patients (8 of 15) in group A and in 87{\%} of patients (13 of 15) in group B. A significant lengthening of the flutter cycle was observed with respect to the baseline in patients given propafenone (261 ± 23 vs 217 ± 25, p <0.01). Sinus rhythm resumed at a shorter paced cycle in group A patients (166 ± 13 vs 187 ± 14 ms, p <0.01). The transesophageal threshold for stable atrial capture was significantly lower in group A (20.5 ± 0.2 vs 23.3 ± 1.2, p <0.01). In no patient was the threshold for atrial capture higher than the pain threshold. We did not observe abrupt enhancement of atrioventricular conduction. We conclude that propafenone is effective and safe when used with transesophageal pacing in the termination of atrial flutter. The slowing effect of the drug on intraatrial conduction and the possible stabilizing effect on the reentry circuit appear to be outweighed by the positive effect of propafenone on the excitable gap of the circuit, facilitating its capture and accounting for the beneficial effect of the drug on arrhythmia termination.",
author = "Flavio Doni and Bella, {Paolo Della} and Antoine Kheir and Margherita Manfredi and Carlo Piemonti and Elio Staffiere and Andrea Rimondini and Cesare Fiorentini",
year = "1995",
month = "12",
day = "15",
doi = "10.1016/S0002-9149(99)80350-6",
language = "English",
volume = "76",
pages = "1243--1246",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "17",

}

TY - JOUR

T1 - Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone

AU - Doni, Flavio

AU - Bella, Paolo Della

AU - Kheir, Antoine

AU - Manfredi, Margherita

AU - Piemonti, Carlo

AU - Staffiere, Elio

AU - Rimondini, Andrea

AU - Fiorentini, Cesare

PY - 1995/12/15

Y1 - 1995/12/15

N2 - Transesophageal overdrive atrial pacing is effective and safe for atrial flutter termination. The influence of antiarrhythmic drug therapy on this procedure is controversial. In this study, we investigated whether oral propafenone may facilitate this procedure. Thirty patients with type I atrial flutter were randomized into 2 groups in which transesophageal pacing was attempted: group A, without treatment; and group B, after oral administration of propafenone 600 mg. Transesophageal pacing was effective in interrupting atrial flutter in 53% of patients (8 of 15) in group A and in 87% of patients (13 of 15) in group B. A significant lengthening of the flutter cycle was observed with respect to the baseline in patients given propafenone (261 ± 23 vs 217 ± 25, p <0.01). Sinus rhythm resumed at a shorter paced cycle in group A patients (166 ± 13 vs 187 ± 14 ms, p <0.01). The transesophageal threshold for stable atrial capture was significantly lower in group A (20.5 ± 0.2 vs 23.3 ± 1.2, p <0.01). In no patient was the threshold for atrial capture higher than the pain threshold. We did not observe abrupt enhancement of atrioventricular conduction. We conclude that propafenone is effective and safe when used with transesophageal pacing in the termination of atrial flutter. The slowing effect of the drug on intraatrial conduction and the possible stabilizing effect on the reentry circuit appear to be outweighed by the positive effect of propafenone on the excitable gap of the circuit, facilitating its capture and accounting for the beneficial effect of the drug on arrhythmia termination.

AB - Transesophageal overdrive atrial pacing is effective and safe for atrial flutter termination. The influence of antiarrhythmic drug therapy on this procedure is controversial. In this study, we investigated whether oral propafenone may facilitate this procedure. Thirty patients with type I atrial flutter were randomized into 2 groups in which transesophageal pacing was attempted: group A, without treatment; and group B, after oral administration of propafenone 600 mg. Transesophageal pacing was effective in interrupting atrial flutter in 53% of patients (8 of 15) in group A and in 87% of patients (13 of 15) in group B. A significant lengthening of the flutter cycle was observed with respect to the baseline in patients given propafenone (261 ± 23 vs 217 ± 25, p <0.01). Sinus rhythm resumed at a shorter paced cycle in group A patients (166 ± 13 vs 187 ± 14 ms, p <0.01). The transesophageal threshold for stable atrial capture was significantly lower in group A (20.5 ± 0.2 vs 23.3 ± 1.2, p <0.01). In no patient was the threshold for atrial capture higher than the pain threshold. We did not observe abrupt enhancement of atrioventricular conduction. We conclude that propafenone is effective and safe when used with transesophageal pacing in the termination of atrial flutter. The slowing effect of the drug on intraatrial conduction and the possible stabilizing effect on the reentry circuit appear to be outweighed by the positive effect of propafenone on the excitable gap of the circuit, facilitating its capture and accounting for the beneficial effect of the drug on arrhythmia termination.

UR - http://www.scopus.com/inward/record.url?scp=0028884685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028884685&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)80350-6

DO - 10.1016/S0002-9149(99)80350-6

M3 - Article

C2 - 7503004

AN - SCOPUS:0028884685

VL - 76

SP - 1243

EP - 1246

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 17

ER -